Monitor launch timeline and initial market share in Canada. The approval positions Dr. Reddy's to capture early generic GLP-1 demand, but pricing and competition dynamics will determine actual financial impact. Watch for updates on U.S. semaglutide approval status.
Price Chart
Executive Summary
Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, the first generic semaglutide authorized in Canada. This expands the company's GLP-1 portfolio and strengthens its position in the global diabetes market, though no financial terms were disclosed.
Key Facts
- First generic semaglutide approved by Health Canada for type 2 diabetes
- Approval covers 2 mg/pen and 4 mg/pen strengths
- API produced in-house; finished product by OneSource Specialty Pharma
- Launch preparations are underway
- Canada is the second-largest market for semaglutide globally (IQVIA)
Financial Impact
Undisclosed; potential for material revenue contribution given Canada's large semaglutide market and first-to-market advantage
Risk Factors
- Competition from other generic entrants
- Pricing pressure from payers and branded discounts
- Manufacturing or supply constraints
- Regulatory delays in other markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000265 |
| Document: 0001575872-26-000265-index.html | 0001575872-26-000265 |
| Document: 0001575872-26-000265.txt | 0001575872-26-000265 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $11.91 $11.55 | ▼ −3.02% | ▼ −2.56% | $12.25 (+2.85%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Aug 26, 2026 5w ago | 6-K | $12.22 $12.16 | ▼ −0.49% | ▼ −1.15% | $12.25 (+0.25%) |
Aug 17, 2026 6w ago | 6-K | $12.11 $12.15 | ▲ +0.33% | ▲ +1.01% | $12.25 (+1.16%) |
Aug 13, 2026 7w ago | 6-K | $12.42 $12.27 | ▼ −1.21% | ▼ −1.01% | $12.25 (−1.37%) |
Aug 10, 2026 7w ago | 6-K | $12.15 $12.45 | ▲ +2.47% | ▲ +2.79% | $12.25 (+0.82%) |
Aug 3, 2026 8w ago | 6-K | $12.07 $12.10 | ▲ +0.25% | ▼ −1.55% | $12.25 (+1.49%) |
Jul 29, 2026 9w ago | 6-K | $11.76 $11.83 | ▲ +0.60% | ▼ −1.08% | $12.25 (+4.17%) |
Jul 23, 2026 10w ago | 6-K | $11.80 $11.79 | ▼ −0.08% | ▼ −0.19% | $12.25 (+3.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access